Announced today results from a Phase 1 scientific trial of APD916.

Adverse events of insomnia, nausea, headache, parosmia, alterations in perception of body’s temperature, abnormal dreams and visible and tactile hallucinations had been commonly reported at the 3 mg and 5 mg doses, and adverse occasions of insomnia were reported at the 1 mg dose commonly. All adverse events in the trial were moderate or moderate in nature. No serious adverse occasions were reported nor have there been any significant safety problems with respect to essential signs, ECGs or laboratory testing. APD916 is an extremely potent substance, and we think that exposures of 1 1 mg or less could be adequate for the intended individual population, said William R.The cost of the program Ahead test is $350.

Case Western Reserve researcher discovers brand-new antivirulence drugs against MRSA and strep Menachem Shoham, PhD, associate professor of biochemistry at Case Western Reserve University School of Medicine, has discovered novel antivirulence medicines that, without killing the bacteria, render Methicillin Resistant Staphylococcus Aureus and Streptococcus pyogenes, referred to as strep commonly, harmless by preventing the production of toxins that cause disease.